摘要
目的探讨维立西呱联合芪苈强心胶囊治疗慢性心力衰竭(CHF)的疗效及对血清氨基末端脑钠肽前体(NT-proBNP)水平的影响。方法选取2023年1月—2024年11月邢台市中心医院心内科诊治的CHF患者106例,采用随机数字表法分成对照组(n=51)和观察组(n=50),对照组在常规治疗基础上应用维立西呱,观察组在对照组基础上联合芪苈强心胶囊。治疗12周后,比较2组临床疗效、阳虚水泛证积分、明尼苏达心力衰竭量表(MLHFQ)评分、心功能指标[左心室射血分数(LVEF)、每搏输出量(SV)]、血清NT-proBNP与血管内皮指标[内皮素-1(ET-1)、一氧化氮(NO)]水平及药物不良反应。结果观察组疗效为94.00%,高于对照组的78.43%(χ^(2)/P=5.125/0.024);治疗12周后,2组阳虚水泛证积分、MLHFQ评分及血清NT-proBNP、ET-1均低于治疗前,且观察组均低于对照组(t/P=6.167/<0.001、8.048/<0.001、3.692/<0.001、4.278/<0.001);2组LVEF、SV、NO均高于治疗前,且观察组均高于对照组(t/P=3.224/0.002、3.382/0.001、2.877/0.005);观察组不良反应发生率为14.00%,与对照组的7.84%比较,差异无统计学意义(χ^(2)/P=0.986/0.321)。结论对CHF患者实施维立西呱联合芪苈强心胶囊治疗的效果较佳,可有效下调血清NT-proBNP水平,明显改善血管内皮功能及相关症状,显著提高心功能及生命质量,且具有安全性。
Objective To investigate the therapeutic effect of the combination of vericiguat and Qili Qiangxin Capsules in treating chronic heart failure(CHF)and its impacts on serum N-terminal pro-B-type natriuretic peptide(NT-proBNP).Methods From January 2023 to November 2024,106 CHF patients treated in our hospital were randomly divided into two groups:the vericiguat group(n=53,received vericiguat in addition to conventional therapy)and the combination group(n=53,received vericiguat plus Qili Qiangxin Capsules).The two groups were compared in terms of therapeutic efficacy,Yang deficiency edema syndrome score,Minnesota Living with Heart Failure Questionnaire(MLHFQ)score,cardiac function indicators[left ventricular ejection fraction(LVEF)and stroke volume(SV)],serum NT-proBNP level,vascular endothelial indicators[endothelin-1(ET-1)and nitric oxide(NO)],and adverse drug reactions.Results The total effective rate in the combination group was 94.00%,which was higher than that in the vericiguat group(78.43%)(χ^(2)/P=5.125/0.024).After treatment,both groups showed decreased scores of Yang deficiency edema syndrome,MLHFQ score,and serum levels of NT-proBNP and ET-1,with the combination group exhibiting lower values than the vericiguat group(t/P=6.167/<0.001,8.048/<0.001,3.692/<0.001,4.278/<0.001).After treatment,both groups showed increased LVEF,SV,and NO levels,with the combination group exhibiting higher values than the vericiguat group(t/P=3.224/0.002,3.382/0.001,2.877/0.005).There was no significant difference in the incidence of adverse reactions between the combination group and the vericiguat group(14.00%vs.7.84%)(P>0.05).Conclusion The combination of vericiguat and Qili Qiangxin Capsules demonstrates better therapeutic efficacy in CHF patients.It can effectively reduce serum NT-proBNP levels,significantly improve vascular endothelial function and related symptoms,enhance cardiac function and quality of life,and is safe.
作者
贺江波
刘立辉
杨湛南
He Jiangbo;Liu Lihui;Yang Zhannan(Department of Cardiology,Xingtai Central Hospital,Hebei,Xingtai 054000,China)
出处
《疑难病杂志》
2025年第9期1040-1044,共5页
Chinese Journal of Difficult and Complicated Cases
基金
河北省医学科学研究课题计划(20251421)。
关键词
慢性心力衰竭
维立西呱
芪苈强心胶囊
氨基末端脑钠肽前体
心功能指标
血管内皮指标
Chronic heart failure
Vericiguat
Qili Qiangxin Capsules
N-terminal pro-B-type natriuretic peptide
Cardiac function indicators
Vascular endothelial indicators
